Trials / Recruiting
RecruitingNCT07211048
Anti CD19 Gene Therapy for B-cell Lymphoma
Early Exploratory Clinical Study of CD19-targeted Gene Injection (LCAR02) in Patients With Relapsed/Refractory B-cell Lymphoma
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Anhui Provincial Hospital · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with treatment of relapsed/refractory B-cell lymphoma. This study aims to evaluate the safety and efficacy of the treatment with an Anti- CD19 gene injection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anti-CD19 gene injection | Intravenous infusion of Anti-CD19 gene injection （three dosage groups） |
Timeline
- Start date
- 2026-03-20
- Primary completion
- 2029-12-31
- Completion
- 2029-12-31
- First posted
- 2025-10-07
- Last updated
- 2026-01-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07211048. Inclusion in this directory is not an endorsement.